HHS’s New 503A Peptide Policy: What It Means for BPC-157, TB-500, and Four Other Peptides

If your feed says peptides are “back,” here’s the part it’s leaving out: an interim policy isn’t U.S. Food and Drug Administration (FDA) approval, and there are additional regulatory considerations that need to be made. On October 28, 2026, the U.S. Department of Health and Human Services (HHS) announced an interim enforcement discretion policy that creates a potential pathway for 503A pharmacies to compound six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.

As a 503A compounding pharmacy, we see it as a meaningful development for patient access, for the industry, and for Strive. We’ve been working behind the scenes to prepare for this opportunity, including advocating in Washington, D.C. for regulated peptide access.

Here’s what the policy covers, what it doesn’t, and how Strive is preparing.

What Is the HHS Peptide Enforcement Discretion Policy for 503A Pharmacies?

The policy is titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” It applies to state-licensed pharmacies, Federal facilities, and licensed physicians while the FDA considers adding six peptides to the 503A Bulks List.

The policy is interim, and it sets detailed expectations for ingredient sourcing, quality, testing, reporting, and other operations. It stays in place until a final rule decides whether each peptide is included on the 503A Bulks List. HHS may revisit the policy, in whole or in part, if a safety signal or product quality issue arises.

HHS filed the policy with the Federal Register on October 28, 2026, and it was published on October 30. Written comments can be submitted through regulations.gov on Docket No. HHS-OASH-2026-0496 until two weeks after publication, which is November 13, 2026.

Skip the headlines and read the record: Federal Register public inspection (PDF), HHS policy appendix (PDF), Federal Register policy page, and PCAC meeting page.

Which Peptides Does the 503A Policy Cover? BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500

The interim policy covers six peptides, and each is limited to a specific form and route of administration. HHS lists the six in Appendix A of the policy. Appendix B defines each peptide’s identity, including its amino acid sequence, molecular formula, and molecular weight.

The Pharmacy Compounding Advisory Committee reviewed seven peptides at its July 2026 meeting. The seventh, Emideltide (also called DSIP), isn’t included in the HHS policy. While its review and vote was only advisory, it does seem to have influenced the peptides included in the interim policy.

503A Peptide Compounding Requirements

Enforcement discretion applies only when every one of these conditions is met:

1. Listed peptide, correct identity and route. The peptide appears in Appendix A and matches the identity and route limits in Appendix B.
2. Verified bulk ingredient. The bulk drug substance comes from an FDA-registered facility with a valid certificate of analysis (COA). The COA covers identity, purity, potency, and the absence of contaminants such as endotoxins, heavy metals, microbial contamination, and impurities.
3. Registered original manufacturer. The original manufacturer, not a later packer, repacker, labeler, or distributor, is FDA-registered and in compliance with current good manufacturing process (cGMP). Its facilities physical location is listed on the COA. A repacker, relabeler, or reseller must document its own validation of the manufacturer and the manufacturer’s COA.
4. Reporting. Compounders report serious adverse events and product quality issues to FDA’s MedWatch program and to the states where products are compounded and sent. Reporting includes the active ingredient and strength, the original manufacturer and its facility identifier, and the dosage form and route.
5. Labeling. Product labeling states, “This is a compounded drug product. Not for resale.” It also explains how patients can report adverse events and quality issues.
6. Single active ingredient. Each compounded product contains only one active pharmaceutical ingredient (API) from Appendix A.
7. Oral bioavailability documentation. For oral dosage forms, the compounder keeps documentation confirming the specific formulation achieves an adequate level of oral bioavailability in humans.
8. Delivery device. The only drug delivery device co-packaged with or containing the product is an FDA 510(k)-cleared syringe.
9. All other requirements. The product meets every other applicable FD&C Act requirement, including a valid patient-specific prescription and compounding under sanitary conditions.

Appendix B also sets a detailed testing standard for what a peptide COA must report, including identity, assay, impurities, residual solvents, elemental impurities, bioburden, and bacterial endotoxins. Some of the policy’s requirements are new, and suppliers will need to develop and verify them.

Are Compounded Peptides FDA-Approved?

No. The interim policy is not FDA approval of these peptides, and compounded preparations are not FDA-approved.

Compounded medications are specially prepared for individual patient needs based on a valid prescription. As such, they are not reviewed or approved by the FDA for safety or efficacy.

Is the Peptide Ban Lifted?

Not exactly. The policy doesn’t approve these peptides or add them to the 503A Bulks List. It’s interim enforcement discretion: a potential pathway for 503A compounding of six peptides, only when every condition in the policy is met, while the FDA considers adding them to the list. HHS may revisit the policy if a safety signal or product quality issue arises.

When Will Strive Offer Compounded Peptides?

Strive will launch once its regulatory and operational readiness is confirmed. The how matters as much as the when, so we’re taking the time to get it right. During this time we are making sure we are actively:

• Reviewing every requirement. We’re confirming the right processes and controls are in place before launching any peptides.
• Building for the long term. The goal is to enter this market the right way and serve patients for years to come. That’s how Strive has always operated.
• Launching when ready. Our goal isn’t to be first, it’s to put quality first for our patients and providers. How we enter the market not only reflects directly on us, but on the compounding industry as a whole.

How Strive Is Preparing for Compounded Peptides

Strive isn’t starting from zero. We’ve invested in:

• Qualification of API suppliers from validated sources
• Formulation research and refinement
• Third-party analytical testing
• Stability studies and quality system development
• Operational planning and regulatory readiness
• Provider education

Learn more about Strive’s approach to compounded peptides.

Compounded Peptide Quality Standards: Sourcing, Testing, and Certificates of Analysis

For those new to Strive, you may not know but industry minimums aren’t our maximums. Here’s what a focus on higher standards, from ingredient to vial, looks like in practice. This is the Strive standard.

Sourcing you can verify. Every ingredient comes from FDA-registered suppliers, and each shipment arrives with a COA. Peptide ingredients come only from qualified, FDA-registered manufacturers that document purity and are verified against their COA. Third-party identity and purity testing is being added to our quality process.

Accountability you can check. Strive compounds in licensed 503A pharmacies, is licensed in every state where its medications are dispensed, and is LegitScript certified. To go beyond minimum requirements, some Strive locations are voluntarily accredited by PCAB (ACHC) and/or NABP/VPP. View pharmacy locations and licenses.

Testing, again and again. Samples from randomly selected sterile batches go to a third-party lab for potency testing multiple times each week. Every sterile batch also undergoes third-party sterility and endotoxin testing.

Quality built in. Beyond-use dating is grounded in stability data. Master formulation records, batch records, and defined release criteria keep every preparation traceable from raw ingredient to final release.

See how Strive’s higher standards work from ingredient to vial.

A Shared Standard for Regulated Peptide Access

Again this policy is interim, and how the industry shows up now will help shape whether regulated peptide access lasts. Strive encourages every compounding pharmacy to approach this opportunity with rigor, compliance, and care for the patients and healthcare providers counting on them, and to hold to a shared standard:

• Know your sources: ingredients from qualified, validated suppliers, with paperwork you can verify
• Test with rigor: testing, including independent third-party testing, that supports consistent quality
• Build quality in from day one: beyond-use dates that follow USP standards, stability data behind any extended dating, and quality oversight before the first preparation, not after
• Communicate responsibly: clear, factual, measured education
• Stay prescription-based: each preparation made for a specific patient on a valid prescription, identified medical need, and following state law

We’ll share updates as our regulatory and operational readiness is confirmed. Learn more about Strive’s approach to compounded peptides.

Disclaimer:

Compounded medications are specially prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Individual outcomes may vary. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA.

This information is intended for informational purposes only and does not constitute medical advice. Strive does not compound peptides for patient use without FDA regulatory authorization or enforcement discretion to do so. Any concentrations and dosing listed reflect Strive's development efforts and development work is ongoing. Production is entirely contingent on the FDA's regulatory posture and formal guidance. Strive will follow the FDA's lead.